Working... Menu

A Study of MK0359 in Patients With Chronic Asthma (0359-013)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00482898
Recruitment Status : Completed
First Posted : June 5, 2007
Last Update Posted : May 27, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
A study to test the effect of MK0359 in lessening the symptoms of asthma as compared to placebo.

Condition or disease Intervention/treatment Phase
Asthma Drug: MK0359 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Crossover Study Comparing the Effect of MK0359 and Placebo in Adult Patients With Chronic Asthma
Study Start Date : September 2002
Actual Primary Completion Date : April 2003
Actual Study Completion Date : April 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • You are between the ages of 18 and 45
  • You have had a history for at least a year of COPD symptoms
  • Your current asthma treatment is limited to short-acting beta-agonists(such as albuterol)
  • You have a history of smoking one pack of cigarettes per day for 7 years
  • You will not be away from home for more than 5 days during the study

Exclusion Criteria:

  • You are unwilling to limit your alcohol use to less than 5 drinks per week
  • You have been in a research study with an investigational drug or vaccine in the last 4 weeks
  • You have donated blood in the last 4 weeks
  • You have been hospitalized or had major surgery in the last 4 weeks
  • You have been treated in the emergency room within the last 4 weeks or hospitalized within the last 3 months for your asthma
  • You have a history of heart problems in the last 6 months
  • You have a history of stomach problems
  • You are unwilling to avoid grapefruit juice throughout the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00482898

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Layout table for investigator information
Study Director: Medical Monitor Merck Sharp & Dohme Corp.

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00482898     History of Changes
Other Study ID Numbers: 0359-013
First Posted: June 5, 2007    Key Record Dates
Last Update Posted: May 27, 2015
Last Verified: May 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases